生物标志物驱动无功能垂体神经内分泌肿瘤精准医学:近期文献系统综述
该系统综述遵循PRISMA 2020在Scopus和Web of Science检索,纳入29项原研研究,将无功能垂体神经内分泌肿瘤的分子发现归为侵袭/EMT、非编码RNA与液体活检、多组学与表观遗传三个主题。综述发现各亚型进展由不同分子网络主导,但多数标志物仍属探索性,需统一方法和多中心验证。
要点
- 促性腺激素细胞瘤EMT活性最强,与SNAI、Vimentin及β-catenin改变相关。
- exosomal miR-486-5p、miR-151a-5p和exosomal MMP1有诊断或预后价值,但亚型特异性有限。
- 多数生物标志物仍为探索性,需统一方法和多中心验证支持精准诊疗。
核心结论
- 无功能垂体神经内分泌肿瘤各亚型通过不同分子通路进展,每个亚型由不同调控网络主导。
- 多数生物标志物仍属探索性,需统一方法和多中心验证以支持精准诊断和预后建模。
研究设计与样本
- 系统综述遵循PRISMA 2020,在Scopus和Web of Science检索,纳入29项原研研究。
主要发现
- 促性腺激素细胞瘤EMT相关活性最强,包括SNAI介导转化、Vimentin上调和β-catenin改变。
- 促肾上腺皮质激素细胞瘤EMT参与程度中等,零细胞瘤侵袭主要由缺氧相关蛋白酶失调驱动而非EMT。
- exosomal miR-486-5p、miR-151a-5p和exosomal MMP1显示诊断或预后价值,但亚型特异性有限。
- 促性腺激素细胞瘤与PI3K-AKT通路富集和SF-1标记异质性相关,复发灶核pEGFR T693和MCM7升高。
- DNA甲基化定位到NUP93、LGALS1和GABRA1等亚型相关位点,磷酸化蛋白组和乙酰化组提示代谢、激酶及细胞黏附通路改变与侵袭和复发相关。
临床怎么用
- 可依据肿瘤亚型对应的分子网络特征辅助预后分层,但不宜将探索性标志物直接用于临床决策。
- 液体活检候选标志物如exosomal miR-486-5p等亚型特异性有限,临床应用前需进一步验证。
局限性
- 多数生物标志物仍为探索性,缺乏统一检测方法。
- 需多中心验证以支持精准诊断和预后建模。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonfunctioning pituitary neuroendocrine tumors (NF-PitNETs) display considerable biological heterogeneity, posing challenges for accurate prognostication and personalized management. This systematic review, conducted in Scopus and Web of Science in accordance with PRISMA 2020, identified 29 primary studies and categorized all molecular findings into 3 core themes: (1) invasion biology and epithelial-mesenchymal transition (EMT); (2) noncoding RNAs and liquid biopsy markers; and (3) multiomics, epigenetic, and prognostic signatures. Within the invasion/EMT theme, gonadotroph tumors consistently demonstrated the strongest EMT-linked activity, including SNAI-mediated transitions, Vimentin upregulation, and β-catenin alterations. Corticotroph tumors showed intermediate EMT involvement, while null-cell tumors exhibited invasion patterns driven mainly by hypoxia-related protease dysregulation rather than EMT. In the noncoding RNA and circulating biomarker theme, several candidates, including exosomal miR-486-5p, miR-151a-5p, and exosomal MMP1, have shown diagnostic or prognostic value, although subtype specificity remains limited. The multiomics and epigenetic theme revealed subtype-dependent molecular programs: gonadotroph tumors were associated with PI3K-AKT pathway enrichment and SF-1 labeling heterogeneity; recurrent lesions showed elevated nuclear pEGFR T693 and MCM7; while DNA methylation mapping identified subtype-relevant loci such as NUP93, LGALS1, and GABRA1. Phosphoproteomic and acetylomic profiling further highlighted alterations in metabolic, kinase-driven, and cell-adhesion pathways linked to invasion and recurrence. Overall, the lineage-aligned synthesis indicates that NF-PitNETs progress through diverse molecular pathways, with each subtype dominated by distinct regulatory networks. Although many biomarkers show promise, most remain exploratory, highlighting the need for harmonized methods and multicenter validation to support precision diagnostics and prognostic modeling.
引用
- Haydar Ali Tajuddin A, Isa NF, Mohd Nasir MH, et al. Biomarkers Driving Precision Medicine in Nonfunctioning Pituitary Neuroendocrine Tumors: A Systematic Review of Recent Literature. J Clin Endocrinol Metab. 2026. PMID: 41342334. doi:10.1210/clinem/dgaf650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。